Atrimed Pharmaceuticals introduces capsule that can inhibit viral replication

Atrimed Pharmaceuticals recently launched Vyvuz capsules, a product licensed by the Drug Authority of Kerala, that has been shown to inhibit the virus by up to 99.9 per cent, a company statement said.

The statement quoted Dr Hrishikesh Damle, MD and CEO, Atrimed Pharma as saying, “…… With the ease of use and affordable price, all primary contacts, those who are travelling, attending gatherings or school-going children, can be protected against the virus with the addition of Vyvuz to the existing measures. Since it is known to be safe, Vyvuz has ingredients that have been tested in the Government of India biotechnology labs and have been shown to inhibit the virus by up to 99.9 per cent.”

This formulation has been tested against the Delta variant and was found to be effective. AI-based studies prove that it is also effective against the ‘Omicron’ variant. The formulation contains Centella Asiatica, Withania Somnifera and Andrographis Paniculata. Atrimed has conducted in-silico, in-vitro, in-vivo, phase-I and phase-II clinical trials. The formulation was proven to be effective in reducing inflammatory markers and hence early symptomatic relief in COVID patients, concluded the statement.